COST EFFECTIVENESS ANALYSIS OF LENVATINIB FOR THE FIRST-LINE TREATMENT OF INDIVIDUALS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA

被引：0
|
作者：
Li, X. [1 ]
Wudong, G. [2 ]
Wang, Y. [2 ]
机构：
[1] Natl Hlth Commiss, Beijing, Peoples R China
[2] China Natl Hlth Dev Res Ctr, Beijing, Peoples R China
来源：
VALUE IN HEALTH | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN77
引用
收藏
页码：S37 / S37
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness analysis of donafenib versus lenvatinib for first-line treatment of unresectable or metastatic hepatocellular carcinoma
    Meng, Rui
    Zhang, Xueke
    Zhou, Ting
    Luo, Mengjie
    Qiu, Yijin
    [J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2022, 22 (07) : 1079 - 1086
  • [2] ASSESSING THE COST-EFFECTIVENESS OF LENVATINIB AS A FIRST-LINE THERAPY FOR UNRESECTABLE HEPATOCELLULAR CARCINOMA IN CANADA
    Kim, John J.
    McFarlane, Thomas
    Tully, Stephen
    Wong, William W. L.
    [J]. MEDICAL DECISION MAKING, 2020, 40 (01) : E3 - E4
  • [3] Lenvatinib Versus Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma: A Cost-Utility Analysis
    Kim, John J.
    McFarlane, Thomas
    Tully, Stephen
    Wong, William W. L.
    [J]. ONCOLOGIST, 2020, 25 (03): : E512 - E519
  • [4] First-line systemic treatment strategies for unresectable hepatocellular carcinoma: A cost-effectiveness analysis
    Wang, Liting
    Peng, Ye
    Qin, Shuxia
    Wan, Xiaomin
    Zeng, Xiaohui
    Li, Sini
    Liu, Qiao
    Tan, Chongqing
    [J]. PLOS ONE, 2023, 18 (04):
  • [5] Cost-effectiveness analysis of sintilimab plus bevacizumab biosimilar compared with lenvatinib as the first-line treatment of unresectable or metastatic hepatocellular carcinoma
    Zhou, Ting
    Wang, Xintian
    Cao, Yingdan
    Yang, Lan
    Wang, Zijing
    Ma, Aixia
    Li, Hongchao
    [J]. BMC HEALTH SERVICES RESEARCH, 2022, 22 (01)
  • [6] Cost-effectiveness analysis of sintilimab plus bevacizumab biosimilar compared with lenvatinib as the first-line treatment of unresectable or metastatic hepatocellular carcinoma
    Ting Zhou
    Xintian Wang
    Yingdan Cao
    Lan Yang
    Zijing Wang
    Aixia Ma
    Hongchao Li
    [J]. BMC Health Services Research, 22
  • [7] Cost-Effectiveness of Donafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma in China
    Guan, Haijing
    Wang, Chunping
    Zhao, Zhigang
    Han, Sheng
    [J]. ADVANCES IN THERAPY, 2022, 39 (07) : 3334 - 3346
  • [8] Cost-Effectiveness of Donafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma in China
    Haijing Guan
    Chunping Wang
    Zhigang Zhao
    Sheng Han
    [J]. Advances in Therapy, 2022, 39 : 3334 - 3346
  • [9] Lenvatinib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
    Wang, Shijie
    Wang, Yiting
    Yu, Jiangtao
    Wu, Huaxing
    Zhou, Yanming
    [J]. CANCERS, 2022, 14 (22)
  • [10] Cost-effectiveness analysis of Tislelizumab vs Sorafenib as the first-line treatment of unresectable hepatocellular carcinoma
    Chen, Qiuping
    Sun, Quan
    Zhang, Jing
    Li, Baixue
    Feng, Quansheng
    Liu, Jibin
    [J]. PLOS ONE, 2024, 19 (03):
12345